WuXi AppTec Co., Ltd. Depositary Receipt (WUXIAT80)

Overview

WuXi AppTec Co., Ltd. stands as a notable investment holding company, significantly contributing to the pharmaceutical and biotechnology sectors by offering a comprehensive suite of research, development, and manufacturing services. Specifically, these services are aimed at the discovery, development, and manufacturing of small molecule drugs, as well as cell and gene therapies. With a global operational footprint, WuXi AppTec has established its presence not only in the People's Republic of China but also in the United States, Europe, and various international markets. Since its inception in 2000, with headquarters in Shanghai, China, the company has progressively expanded its capabilities and service offerings across multiple segments in the pharmaceutical and biotechnological development pipeline.

Products and Services

WuXi AppTec Co., Ltd. provides a diverse portfolio of services across its segments to cater to the dynamic needs of the drug and medical device development sectors:

• WuXi Chemistry: Specializes in offering services for the discovery, development, and manufacturing of small molecules, oligonucleotides, peptides, and complex conjugates. This includes synthetic molecular modalities across various drug development stages, from initial discovery to commercial production.
• WuXi Testing: Provides comprehensive drug and medical device testing services, supporting projects from the preclinical testing phase through to clinical trials. This ensures that products meet the regulatory standards required for market approval.
• WuXi Biology: Offers a range of biology services and solutions that support projects from the stage of target discovery through to candidate selection, and into clinical development phases. This segment facilitates both standalone and integrated project support to streamline the drug development process.
• WuXi ATU (Advanced Therapies Unit): Delivers an integrated solution designed to accelerate the development and commercialization of cell and gene therapies. This comprehensive service offering covers the entire lifecycle of advanced therapeutic products.
• WuXi DDSU (Drug Discovery and Development Services Unit): Provides drug discovery services tailored to the needs of pharmaceutical and biotech clients, assisting in the identification and development of novel drug candidates. This unit leverages WuXi AppTec’s extensive experience and technological capabilities to support the early stages of drug development.
• Others: This segment encompasses a range of additional services and capabilities that WuXi AppTec offers. It includes specialized services that do not neatly fit into the other categories but are essential components of the company's comprehensive offerings to the pharmaceutical and biotechnology sectors.